“Breast Cancer Talk”: Nursing Perspectives on HER2-Targeted Agents in Breast Cancer

home / the-talk / breast-cancer-talk-nursing-perspectives-on-her2-targeted-agents-in-breast-cancer

Practical Management of Early Stage HER2+ Breast Cancer

EP. 1: Practical Management of Early Stage HER2+ Breast Cancer

By Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology
Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center

September 23rd 2020

HER2-targeted Therapy: Routes of Administration

EP. 2: HER2-targeted Therapy: Routes of Administration

By Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology
Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center

September 23rd 2020

$FDA-approved Therapies for Relapsed/Refractory HER2+ mBC$

EP. 3: FDA-approved Therapies for Relapsed/Refractory HER2+ mBC

By Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology
Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center

September 23rd 2020

Management of Adverse Effects in R/R HER2+ mBC

EP. 4: Management of Adverse Effects in R/R HER2+ mBC

By Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology
Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center

September 23rd 2020

Latest Conference Coverage

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.